Online inquiry

IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2223MR)

This product GTTS-WQ2223MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets VWF gene. The antibody can be applied in Acute coronary syndrome (ACS), Thrombotic thrombocytopenia purpura (TTP) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000552.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7450
UniProt ID P04275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2223MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1494MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ2799MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ9198MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ11720MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ9289MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ9112MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ5727MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ5756MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW